Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has announced that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, has received approval from the Danish Medicines Agency.
Subscribe to our email newsletter
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received national regulatory approval in Denmark.
The Danish Medicines Agency approved label for Toctino indicates ‘for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids’.
Marketing applications for the use of Toctino (alitretinoin) in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.